Source:Journal of Allergy and Clinical Immunology
Author(s): Lennart M. Roesner, Petra Kienlin, Gabriele Begemann, Oliver Dittrich-Breiholz, Thomas Werfel
Teaser
Topical formulations of the two PDE4i roflumilast and TAK-084 lead to a reduction of inflammatory markers and infiltrating cells in psoriatic lesional skin.http://ift.tt/2puH4yR
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου